A research programme by the Access to Medicine Foundation
The foundation

Access to Medicine Foundation

The Foundation stimulates and guides pharmaceutical companies to do more to improve access to medicine. It is an independent non-profit organisation.
Our programmes

Access to Medicine Index

Ranks 20 of the world’s largest pharmaceutical companies based on their efforts to address access to medicine, including in strategy, governance, R&D and pricing. By publicly recognising the best performers, the Index spurs companies to compete to be the best.

Antimicrobial Resistance Benchmark

Tracks what the 17 most active companies in antimicrobial R&D and manufacturing are doing to bring antimicrobial resistance under control. By assessing the level of action, it provides a reality check on progress against AMR.

Access to Vaccines Index

Reports what vaccine companies are doing to ensure all children can be immunised wherever they live. By uncovering what is working and where, this Index helps ensure vaccine markets also reach the poorest and most remote communities.
Type search term(s) and press enter
Often searched for
Index Ranking Vacancies 10-year analysis R&D pipelines AMR antibiotics Investors
  • Publications
  • Why it matters – Pharmaceutical Compliance, A...
Published on 07 Nov 2017
Share
Publication

Why it matters – Pharmaceutical Compliance, Anti-corruption and Access to Medicine

In the article, Luca Genovese and Danny Edwards, Researchers at the Access to Medicine Foundation, discuss the role of pharmaceutical companies in limiting corrupt acts and unethical behaviour to mitigate their harmful impact on access to medicine in low- and middle-income countries.

Explore further

Publication

Harvard Business Review: How pharma can fix its reputation and its business at the same time

Could transforming access to medicine to a fully-fledged business strategy help pharma companies enhance shareholder value? Damiano de Felice, Strategy Director, examines in his article for Harvard Business Review.
Publication

Stanford Social Innovation Review: Access by Prescription

In the article, Jayasree K. Iyer, Executive Director at the Access to Medicine Foundation, describes the corporate strategies that large pharmaceutical companies use to make medicines and vaccines accessible for people living in low- and middle-income countries. In this piece, she identifies the steps that companies can and typically do take when creating an effective access-to-medicine strategy.

Back to top |